Zobrazeno 1 - 10
of 91
pro vyhledávání: '"Christopher J, Winrow"'
Autor:
Katy Phelan, Luigi Boccuto, Craig M. Powell, Tobias M. Boeckers, Conny van Ravenswaaij-Arts, R. Curtis Rogers, Carlo Sala, Chiara Verpelli, Audrey Thurm, William E. Bennett, Christopher J. Winrow, Sheldon R. Garrison, Roberto Toro, Thomas Bourgeron
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 17, Iss 1, Pp 1-4 (2022)
Abstract Phelan-McDermid syndrome (PMS) was initially called the 22q13 deletion syndrome based on its etiology as a deletion of the distal long arm of chromosome 22. These included terminal and interstitial deletions, as well as other structural rear
Externí odkaz:
https://doaj.org/article/399efd35b13d49aca4c80ce2e31e1dfa
Autor:
Susana S. Correia, Guang Liu, Sarah Jacobson, Sylvie G. Bernier, Jenny V. Tobin, Chad D. Schwartzkopf, Emily Atwater, Elisabeth Lonie, Sam Rivers, Andrew Carvalho, Peter Germano, Kim Tang, Rajesh R. Iyengar, Mark G. Currie, John R. Hadcock, Christopher J. Winrow, Juli E. Jones
Publikováno v:
Journal of Neuroinflammation, Vol 18, Iss 1, Pp 1-13 (2021)
Abstract Background Inflammation in the central nervous system (CNS) is observed in many neurological disorders. Nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO–sGC–cGMP) signaling plays an essential role in modulating n
Externí odkaz:
https://doaj.org/article/b9dc10997df94c7186de03737efe4dd1
Autor:
Susana S. Correia, Rajesh R. Iyengar, Peter Germano, Kim Tang, Sylvie G. Bernier, Chad D. Schwartzkopf, Jenny Tobin, Thomas W.-H. Lee, Guang Liu, Sarah Jacobson, Andrew Carvalho, Glen R. Rennie, Joon Jung, Paul A. Renhowe, Elisabeth Lonie, Christopher J. Winrow, John R. Hadcock, Juli E. Jones, Mark G. Currie
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Effective treatments for neurodegenerative diseases remain elusive and are critically needed since the burden of these diseases increases across an aging global population. Nitric oxide (NO) is a gasotransmitter that binds to soluble guanylate cyclas
Externí odkaz:
https://doaj.org/article/77b2ed6c8b9c4de4b87274d76d632880
Autor:
Masashi Yanagisawa, Christopher J. Winrow, Neil Upton, Gregor Sutcliffe, Jerome M Siegel, Takeshi Sakurai, John Renger, Rod Porter, Terrence P. McDonald, Jyrki P. Kukkonen, Thomas Kilduff, Laura Jacobson, Daniel Hoyer, Debbie Hartman, Luis De Lecea, Paul Coleman, Pascal Bonaventure, Gary Aston-Jones
Publikováno v:
IUPHAR/BPS Guide to Pharmacology CITE. 2023
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [43]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4494e816ff2e1ff073075e99b23a0035
https://doi.org/10.2218/gtopdb/f51/2023.1
https://doi.org/10.2218/gtopdb/f51/2023.1
Autor:
Jan Hoffmann, Weera Supronsinchai, Simon Akerman, Anna P. Andreou, Christopher J. Winrow, John Renger, Richard Hargreaves, Peter J. Goadsby
Publikováno v:
Neurobiology of Disease, Vol 74, Iss , Pp 137-143 (2015)
Objective: To examine the effect of the orexinergic blockade with a dual orexin receptor antagonist (DORA) on experimental models of peripheral and central trigeminal as well as cortical activation relevant to migraine and migraine aura. Methods: In
Externí odkaz:
https://doaj.org/article/1a2a11ed12c6498797f502c636145836
Autor:
Jim J. Hagan, John J. Renger, Thomas S. Kilduff, Paul J. Coleman, Jerome M. Siegel, Jyrki P. Kukkonen, Christopher J. Winrow, Luis de Lecea, Daniel Hoyer, Roderick A. Porter, Anthony L. Gotter, Gregor J Sutcliffe, Neil Upton
Publikováno v:
IUPHAR BPS Guide Pharm CITE
Orexin receptors (nomenclature as agreed by the NC-IUPHAR Subcommittee on Orexin receptors [42]) are activated by the endogenous polypeptides orexin-A and orexin-B (also known as hypocretin-1 and -2; 33 and 28 aa) derived from a common precursor, pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1196f26965e8dd135a136421a8771cb
https://doi.org/10.2218/gtopdb/f51/2021.3
https://doi.org/10.2218/gtopdb/f51/2021.3
Publikováno v:
Frontiers in Neuroscience, Vol 8 (2014)
Externí odkaz:
https://doaj.org/article/2471423c00ee4ff68037949691c10a1b
Autor:
Pamela L. Tannenbaum, Joanne eStevens, Jacquelyn eBinns, Alan eSavitz, Susan L Garson, Steven V Fox, Paul eColeman, Scott D Kuduk, Anthony L Gotter, Michael eMarino, Spencer J Tye, Jason eUslaner, Christopher J Winrow, John J Renger
Publikováno v:
Frontiers in Behavioral Neuroscience, Vol 8 (2014)
The ability to awaken from sleep in response to important stimuli is a critical feature of normal sleep, as is maintaining sleep continuity in the presence of irrelevant background noise. Dual orexin receptor antagonists (DORAs) effectively promote s
Externí odkaz:
https://doaj.org/article/bc2e2cdd06ec407c9158c769a6c72cea
Autor:
Andrew Carvalho, Kim Tang, Christopher J. Winrow, John R. Hadcock, Sarah Jacobson, Jenny Tobin, Elisabeth Lonie, Sylvie G. Bernier, Thomas W.-H. Lee, Susana S. Correia, Rennie Glen Robert, Chad D. Schwartzkopf, Joon Jung, Peter Germano, Guang Liu, Juli E. Jones, Mark G. Currie, Paul Allan Renhowe, Rajesh R. Iyengar
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Frontiers in Pharmacology
Frontiers in Pharmacology
Effective treatments for neurodegenerative diseases remain elusive and are critically needed since the burden of these diseases increases across an aging global population. Nitric oxide (NO) is a gasotransmitter that binds to soluble guanylate cyclas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f32016c7ebcec298b36c97328d53b8a4
https://www.frontiersin.org/articles/10.3389/fphar.2021.656561/full
https://www.frontiersin.org/articles/10.3389/fphar.2021.656561/full
Autor:
Andres D. Ramirez, Anthony L. Gotter, Steven V. Fox, Pamela L. Tannenbaum, Lihang eYao, Spencer J. Tye, Terrence eMcDonald, Joseph eBrunner, Susan L. Garson, Duane R. Reiss, Scott D. Kuduk, Paul J. Coleman, Jason M. Uslaner, Robert eHodgson, Susan E. Browne, John J. Renger, Christopher J. Winrow
Publikováno v:
Frontiers in Neuroscience, Vol 7 (2013)
Dual orexin receptor antagonists (DORAs) are a potential treatment for insomnia that function by blocking both the orexin 1 and orexin 2 receptors. The objective of the current study was to further confirm the impact of therapeutic mechanisms targeti
Externí odkaz:
https://doaj.org/article/7a637e4e89e342579deeac811d80cf1d